Evaluating the Pharmacokinetics and Safety of Miricorilant

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Corcept Therapeutics
Study ID
NCT07553663
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
  • Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Miricorilant — DRUG
    Single dose of 60 mg miricorilant

Study Details

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Key Dates

Start date
Apr 30, 2026
Status verified
May 2026
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Miricorilant 60mg
    Patients who meet the entry criteria for study CORT118335-863 will be administered a single dose of 60 mg miricorilant.

Primary Outcome Measure

Assessment of miricorilant PK parameters [ Time Frame: Day 1- Day 4 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Site# 433San AntonioTexas78215-

Find similar trials in San Antonio, TX

By research site
Site# 433· San Antonio, TX

Related Studies